ESMO Media Releases

Durvalumab improves progression-free survival in patients with locally advanced, unresectable stage III lung cancer, according to late-breaking results from the phase III PACIFIC trial presented today at the ESMO 2017 Congress in Madrid (1) and published in the New England Journal of Medicine. 

The preliminary results of a study to be presented at the ESMO 2017 Congress in Madrid (1) show that socio-psychological factors have become more significant for patients today than physical side effects such as nausea and vomiting, which were among the top concerns in similar studies carried out previously

Osimertinib improves progression-free survival by 54% compared to standard first line therapy in patients with EGFR mutated non-small-cell lung cancer (NSCLC), according to late-breaking results from the FLAURA trial presented today at the ESMO 2017 Congress in Madrid.

A new tool to identify patients who would benefit from early palliative care will be presented at the ESMO 2017 Congress in Madrid. 

Factors that limit the work ability of young adult cancer survivors are reported today at the ESMO 2017 Congress in Madrid.

The debate on duration of adjuvant chemotherapy for colon cancer is featured in a Special Session at the ESMO 2017 Congress in Madrid.

Patients with high risk prostate cancer starting long-term hormone therapy may benefit from two new treatments, according to late-breaking results from the STAMPEDE trial presented at the ESMO 2017 Congress in Madrid.

Rucaparib maintenance therapy increases progression-free survival in BRCA mutant recurrent ovarian cancer by 77%, according to late-breaking results from the ARIEL3 trial reported today at the ESMO 2017 Congress in Madrid.

Thanks to DNA sequencing, patients with rare cancers for which no standard treatment is available could receive existing therapies that work in patients treated for different cancers, but who carry the same genetic mutations.

Adding taselisib to letrozole before surgery significantly improved outcomes for patients with early breast cancer that was both estrogen receptor positive and HER2-negative (ER+/HER2-) according to results of the LORELEI trial, presented at the ESMO 2017 Congress in Madrid.

The superiority of docetaxel based triplet therapy over standard care in patients with resectable oesophago-gastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the ESMO 2017 Congress in Madrid.

Pembrolizumab has shown a promising response rate in patients with pretreated metastatic gastric cancer, according to late-breaking results from the KEYNOTE-059 trial presented today at the ESMO 2017 Congress in Madrid.